Valion Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Valion Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
- Valion Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares.
- Valion Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2022-12-31 was -55.69K shares.
- Valion Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 0.00 shares.
- Valion Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 563.00 shares, a 99.86% decline from fiscal 2021.
- Valion Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 396.98K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-14 | |
| 2024-12-31 | 0.00 shares 10-K · filed 2026-03-30 | |
| 2022-12-31 | -55.69K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | 563.00 shares 10-K · filed 2024-03-25 |
| 2021-12-31 | 396.98K shares 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |